Results 1 to 10 of about 4,120 (162)

Lanthanum carbonate to control plasma and urinary oxalate level in type 1 primary hyperoxaluria? [PDF]

IJU Case Reports, 2021
Introduction The therapy to reduce urinary oxalate excretion in primary hyperoxaluria type 1 is still required. Case presentation A 37‐year‐old hemodialyzed man suffered from systemic oxalosis secondary to primary hyperoxaluria type 1 exhibited a drastic
Agnieszka Pozdzik, Cristina David, Jelle Vekeman, Frederik Tielens, Michel Daudon   +4 more
doaj   +4 more sources

Gastric lanthanosis (lanthanum deposition) in an immunosuppressed patient that discontinued lanthanum carbonate seven years ago [PDF]

Clinical Case Reports, 2021
A 72‐year‐old female patient used the oral phosphate binder lanthanum carbonate for 6 years, before discontinuing it after receiving a pancreas and kidney transplant. Now, 7 years after discontinuation, the patient developed bilious emesis.
Joana M. Ullmann, Andreas Erbersdobler
doaj   +3 more sources

Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease [PDF]

Therapeutics and Clinical Risk Management, 2020
Valeria Cernaro, Sebastiano Calimeri, Alfredo Laudani, Domenico Santoro Unit of Nephrology and Dialysis, Department of Clinical and Experimental Medicine, University of Messina, Messina, ItalyCorrespondence: Valeria CernaroUnit of Nephrology and Dialysis,
Cernaro V, Calimeri S, Laudani A, Santoro D   +3 more
doaj   +4 more sources

Iron parameters in patients with end-stage renal disease receiving lanthanum carbonate or other non-iron-based phosphate binders: Results from a phase 3, randomized open-label study [PDF]

SAGE Open Medicine, 2018
Objectives: The recent availability of iron-based phosphate binders has raised some concerns about iron overload in patients with end-stage renal disease.
Rosamund J Wilson, Beverly Jones, Claudio Marelli   +2 more
doaj   +4 more sources

Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease—A Comparative Clinical Study [PDF]

Pharmacy, 2023
(1) Background: Hyperphosphatemia is correlated with an increased rate of mortality and morbidity due to cardiovascular diseases in chronic kidney disease (CKD) patients.
Parminder Nain, Narendra Nayak, Mary C. Maj, Rohit Kumar Singh, Jaspreet Kaur, Yujin Jeong, Sabyasachi Maity, Reetuparna Nath, Robert H. Hilgers, Shreya Nauhria, Samal Nauhria   +10 more
doaj   +2 more sources

Lanthanum Carbonate Opacities—A Systematic Review [PDF]

Diagnostics, 2022
Background: Lanthanum carbonate is a phosphate binder used in advanced kidney disease. Its radiopaque appearance has been described in many case studies and case series.
Jan Kampmann, Nina Pirschel Hansen, Anders Nikolai Ørsted Schultz, Andreas Hjelm Brandt, Frans Brandt   +4 more
doaj   +2 more sources

Safety and efficacy of a feed additive consisting of lanthanum carbonate octahydrate (Lanthan One) for cats (Porus GmbH) [PDF]

EFSA Journal, 2022
Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of lanthanum carbonate octahydrate (Lanthan One) as a zootechnical feed additive for cats.
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Vasileios Bampidis, Giovanna Azimonti, Maria de Lourdes Bastos, Henrik Christensen, Birgit Dusemund, Mojca Fašmon Durjava, Maryline Kouba, Marta López‐Alonso, Secundino López Puente, Francesca Marcon, Baltasar Mayo, Alena Pechová, Mariana Petkova, Fernando Ramos, Yolanda Sanz, Roberto Edoardo Villa, Ruud Woutersen, Gabriele Aquilina, Montserrat Anguita, Jordi Tarrés‐Call, Maria Vittoria Vettori, Jaume Galobart   +22 more
doaj   +2 more sources

Lanthanum Carbonate

Annals of Pharmacotherapy, 2006
Objective: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of lanthanum carbonate, a phosphate binder for chronic kidney disease (CKD). Data Sources: Information was selected from PubMed (1965–October 2005). All studies presented as scientific posters and abstracts from nephrology meetings from 1999 to 2005 were also
Melanie S, Joy, Abhijit, Kshirsagar, Corina, Candiani, Tyson, Brooks, Joanna Q, Hudson   +4 more
europepmc   +5 more sources

Safety and efficacy of a feed additive consisting of lanthanum carbonate octahydrate for dogs (Porus GmbH) [PDF]

EFSA Journal
Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of lanthanum carbonate octahydrate as a zootechnical feed additive for dogs.
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Vasileios Bampidis, Giovanna Azimonti, Maria de Lourdes Bastos, Henrik Christensen, Mojca Durjava, Birgit Dusemund, Maryline Kouba, Marta López‐Alonso, Secundino López Puente, Francesca Marcon, Baltasar Mayo, Alena Pechová, Mariana Petkova, Fernando Ramos, Roberto Edoardo Villa, Ruud Woutersen, Orsolya Holczknecht, Fabiola Pizzo, Maria Vittoria Vettori, Jaume Galobart   +20 more
doaj   +2 more sources

Lanthanum carbonate oral powder: satisfaction, preference and adherence in French and Spanish patients with end-stage renal disease [PDF]

Drugs in Context, 2016
Background: Phosphate binders, such as lanthanum carbonate, control elevated serum-phosphate levels in patients with end-stage renal disease (ESRD). Lanthanum carbonate is available in oral powder and tablet form.
Michael Keith, Patricia de Sequera, Francois Clair, Riccardo Pedersini   +3 more
doaj   +2 more sources